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Maintenance of genome stability depends on an 
appropriate response to DNA damage and, when 
insuffi   cient, may lead to development of neo-
plasia. A double-strand break (DSB) is thought to 
be one of the most severe forms of DNA dam  -
age. There are two major types of DSB   repair 
mechanisms: homologous recombination (HR) 
and nonhomologous end joining (NHEJ). The 
fundamental diff  erence between HR and NHEJ 
is the dependence on DNA homology in the 
former. HR is considered error free and is most 
active in the late S/G2 phase of the cell   cycle. 
NHEJ, on the other hand, utilizes little or no 
sequence homology and is active throughout 
the whole cell cycle. Proteins known to be in-
volved in NHEJ include Ku70, Ku80, DNA-
PKcs, artemis, the Mre11–Rad50–Nbs1 com-
plex, DNA ligase IV, and XRCC4 (1).
During development of the immune sys-
tem, mechanisms for genomic stability are ex-
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ploited to generate genetic diversity. During 
early T and B lymphocyte development, V(D)J 
recombination takes place to assemble variable 
(V) exons of the T cell receptor and Ig genes, 
respectively, giving rise to a large repertoire of 
specifi  cities. In B cells, two additional mecha-
nisms, which are activated after antigen recog-
nition, further diversify the antibody response: 
class switch recombination (CSR) and somatic 
hypermutation (SHM). CSR allows a  previously 
rearranged Ig heavy chain V domain to be ex-
pressed in association with a diff  erent constant 
(C) region, leading to production of diff  erent 
isotypes (IgG, IgA or IgE), without changing 
the antibody specifi  city. In SHM, the V domains 
of immunoglobulins may increase their affi   nity 
by accumulation of mutations. 
CSR and SHM are both initiated by a single 
B cell–specifi  c factor, activation-induced cyti-
dine deaminase (AID) (2), probably by deami-
nation of dC residues within the Ig locus (3–5). 
Depending on which way the initial dU/dG 
<doi>10.1084/jem.20050595</doi><aid>20050595</aid>Disparate roles of ATR and ATM in 
immunoglobulin class switch recombination 
and somatic hypermutation
Qiang Pan-Hammarström,1 Aleksi Lähdesmäki,1 Yaofeng Zhao,1 
Likun Du,1 Zhihui Zhao,1 Sicheng Wen,1 Victor L. Ruiz-Perez,2 
Deborah K. Dunn-Walters,3 Judith A. Goodship,2 and Lennart Hammarström1
1Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, SE-14186 
Stockholm, Sweden
2Institute of Human Genetics, Newcastle University, Newcastle-upon-Tyne NE1 3B2, England, UK
3Dept. of Immunobiology, King’s College London School of Medicine, Guy’s Hospital, London SE1 9RT, England, UK
Class switch recombination (CSR) and somatic hypermutation (SHM) are mechanistically 
related processes initiated by activation-induced cytidine deaminase. Here, we have studied 
the role of ataxia telangiectasia and Rad3-related protein (ATR) in CSR by analyzing the 
recombinational junctions, resulting from in vivo switching, in cells from patients with 
mutations in the ATR gene. The proportion of cells that have switched to immunoglobulin 
(Ig)A and IgG in the peripheral blood seems to be normal in ATR-defi  cient (ATRD) patients 
and the recombined S regions show a normal “blunt end-joining,” but impaired end joining 
with partially complementary (1–3 bp) DNA ends. There was also an increased usage of 
microhomology at the 𝗍-𝗂 switch junctions, but only up to 9 bp, suggesting that the end-
joining pathway requiring longer microhomologies (≥10 bp) may be ATR dependent. The 
SHM pattern in the Ig variable heavy chain genes is altered, with fewer mutations occur-
ring at A and more mutations at T residues and thus a loss of strand bias in targeting A/T 
pairs within certain hotspots. These data suggest that the role of ATR is partially overlap-
ping with that of ataxia telangiectasia–mutated protein, but that the former is also 
  endowed with unique functional properties in the repair processes during CSR and SHM.
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mismatch is resolved, it will result in introduction of muta-
tions in the V region genes (SHM) or recombination of the 
two switch (S) regions (CSR). At least three pathways (NHEJ, 
base excision repair, and mismatch repair) have been impli-
cated in processing, repair, and ligation of the broken DNA 
ends (for review see reference 6). However, the way in which 
these pathways are regulated and coordinated to mediate CSR 
and /or SHM are still not well understood.
The ataxia telangiectasia mutated (ATM) protein, a phos    -
phoinositol 3-kinase–like kinase (PIKK), is a master regu-
lator of the DSB response signal transduction pathway. This 
kinase has been suggested to have a role in CSR, as patients 
with ataxia-telangiectasia (A-T), who carry mutations in 
ATM (7), frequently show defi  ciency of serum IgA, IgG2, 
IgG4, and IgE (8). The Sμ-Sα recombination junctions 
from A-T patients are characterized by a strong dependence 
on microhomologies and are devoid of normally occurring 
mutations around the breakpoint, suggesting that ATM 
might be directly involved in the end joining process in 
CSR (9). Recently, ATM (10, 11) and its three substrates, 
Nbs1 (9, 12–15), H2AX (16), and 53BP1 (17, 18) have all 
been implicated in CSR, further supporting the notion that 
ATM-depended pathways are involved in the recombina-
tion process.
The CSR defect in NBS- or 53BP1-defi  cient cells ap-
pears more severe than in ATM-defi  cient cells (9, 17), sug-
gesting possible roles for other upstream PIKKs in CSR. 
Indeed, DNA-PKcs (DNA-dependent protein kinase cata-
lytic subunit) has been implicated in both V(D)J recombina-
tion and CSR (19, 20), possibly through its role in NHEJ. 
Another more closely related PIKK, ataxia telangiectasia 
and Rad3-related protein (ATR), which shares several sub-
strates with ATM (21) (including H2AX and 53BP1), could 
potentially respond to DNA damage in a redundant or over-
lapping manner. Its role in CSR, however, has not been pos-
sible to study, as loss of ATR in mice results in embryonic 
lethality (22, 23).
The SHM process is largely normal in cells defi  cient in 
ATM (24), H2AX(16), 53BP1(17), and DNAPKcs (25), sug-
gesting that the ATM-dependent pathways and the classical 
NHEJ pathway are probably dispensable for this process. The 
role of ATR in SHM has, however, not been possible to 
study because of lack of a suitable experimental system.
Recently, two consanguineous families with Seckel syn-
drome were found to carry mutations in the ATR gene (26). 
This syndrome is a rare autosomal recessive disorder charac-
terized by intrauterine growth retardation, dwarfi  sm, micro-
cephaly, “bird-like” facial features, and mental retardation. A 
subgroup of patients with Seckel syndrome may also manifest 
pancytopenia (27), chromosomal instability (27, 28), and he-
matological malignancies (29). To search for a potential func-
tional role of ATR in CSR and SHM, we performed a detailed 
analysis of μ-α switch (S) recombination junctions and base 
pair substitutions in Ig variable heavy chain (VH) genes, in 
cells from three of the fi  ve ATR-defi  cient (ATRD) patients 
identifi  ed to date.
RESULTS
The numbers of clones switched to IgA in ATRD patients 
are normal
The number of Sμ-Sα fragments was determined from 10 
PCR reactions run in parallel, using DNA (30 ng per reac-
tion) from the same individual. This method can be used to 
estimate the number of clones that have switched to IgA (30). 
Because of the polyclonal nature of the rearrangements at the 
Sμ-Sα region, diff  erently sized switch fragments are ampli-
fi  ed and visualized. The number of clones that have switched 
from IgM to IgA in ATRD patients appears to be similar to 
controls. A typical run is shown in Fig. 1, where at least 11 
distinct Sμ-Sα fragments were amplifi  ed from the control 
and at least 10 fragments were amplifi  ed from the ATRD1 
patient. The experiments were repeated three times for each 
patient. The average numbers of Sμ-Sα fragments generated 
from ATRD1 and ATRD2 were 11.3 and 8.7, respectively, 
with an average of 10.0, which is similar to controls (7–15, av        -
erage:11.8). Thus, the proportion of cells that have switched 
to IgA in the peripheral blood in ATRD patients, at the time 
of sampling, appears to be normal.
S𝗍-S𝗂 recombination junctions in ATRD patients
We subsequently cloned and sequenced 40 S fragments (39 
Sμ-Sα and 1 Sμ-Sγ-Sα) from ATRD1 and ATRD2, gen-
erated in the aforementioned PCR reactions. All the S 
  fragment sequences were unique and therefore represent in-
dependent CSR events (Fig. S1, available at http://www.
jem.org/cgi/content/full.jem20050595/DC1). The S junc-
tions from controls (n = 154), used for comparison, have 
been published previously (9, 13).
Switching to α1 occurred more frequently than to α2 
in ATRD patients as compared with controls (80 vs. 66%). 
However, this diff  erence was not statistically signifi  cant. The 
frequency of additional intra-Sα region recombination, as 
judged by the number of Sμ-Sα-Sα fragments identifi  ed, 
seems to be slightly reduced as compared with controls (5 and 
11%, respectively), but not to a signifi  cant degree.
We subsequently analyzed the microhomology usage at 
the Sμ-Sα junctions in the ATRD patients. There was a sig-
nifi  cant increase in the extent of donor–acceptor homology 
at the Sμ-Sα junctions from ATRD patients; the average 
length of overlap being 3.0 ± 3.8 bp in ATRD and 1.8 ± 
3.2 bp in control B cells (P < 0.05, Student’s t test). The 
junctions from ATRD patients showed a signifi  cantly in-
creased usage of microhomology (≥4 bp) (Table I, 26 + 10 + 
3 = 39 vs. 20% in controls, χ2 test, P < 0.05) as compared 
with controls. Interestingly, this was mainly because of ho-
mologies encompassing 4–6 bp (separated in Fig. 2 A, 26 vs. 
10% in controls, χ2 test, P < 0.01) and, to a much lesser 
degree, 7–9 bp. However, there was no increased usage of 
longer microhomologies (i.e., ≥10 bp) at the junctions from 
the patients as compared with controls (Fig. 2 A and Table I). 
When the data was plotted as an accumulative curve, it is evi-
dent that the proportion of S junctions with longer homol-
ogies was almost the same as in controls (Fig. 2 B).JEM VOL. 203, January 23, 2006  101
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Mutations at or close to the S𝗍-S𝗂 junctions (±15 bp) 
from ATRD patients
In ATRD patients, the number of S junctions with mutations 
was signifi  cantly smaller than in controls (18 vs. 39%, χ2 test, 
P < 0.05), whereas insertions were observed at a similar rate 
(23 vs. 25%) (Table I). The frequencies of mutations or inser-
tions around the junctions were 13.7 and 22.9/1,000 bp for 
ATRD and controls, respectively. The number of mutations 
and insertions available for analysis was too low in the patient 
group (n = 13) to allow a formal analysis of the pattern of nu-
cleotide alterations.
Mutations in the S𝗍 region (>15 bp upstream of the 
switch junctions) in ATRD patients
The mutation pattern in the Sμ region (upstream of the 
breakpoints, referred to as SHM-like mutations) resembles 
that in the V regions and is clearly diff  erent from that at, or 
close to, the Sμ-Sα breakpoints (13, 24), suggesting that the 
former mutations occur at an early step during CSR (12). 
In ATRD patients, SHM-like mutations in the Sμ region 
were observed at a signifi  cantly lower frequency than in 
controls (3.1/1,000 bp vs. 6.5/1,000 bp; χ2 test, P < 0.001). 
In the few mutations observed (n = 25), the general pattern 
of base substitution seems to be slightly diff  erent from con-
trols, with a stronger, but statistically nonsignifi  cant, pre-
ference for G/C sites (72 vs. 62% in controls), a reduced 
number of mutations at A nucleotides (12 vs. 21% in con-
trols) and an increased frequency of mutations at G nucleo-
tides (40 vs. 28%).
The mutations in the Sμ region from ATRD patients 
were less often associated with the previously described con-
sensus hotspot for SHM, the RGYW/WRCY (R = A or G, 
Y = C or T, W = A or T) motif (31), as compared with con-
trols (56 and 70% for ATRD and controls, respectively), but 
not to a signifi  cant degree.
Characterizations of S𝗍-S𝗄 junctions in ATRD patients
We have previously designed a series of PCRs that specifi  -
cally amplify Sμ-Sγ1, Sμ-Sγ2, and Sμ-Sγ3 fragments from 
DNA from peripheral blood cells. The number of clones that 
have switched to the diff  erent IgG subclasses in ATRD pa-
tients appears to be similar to controls (not depicted). We 
subsequently cloned and sequenced 49 Sμ-Sγ fragments from 
the ATRD patients. 48 of these fragments were unique in 
their junctional sequences and most were a result of direct 
switching to IgG1 (n = 17), IgG2 (n = 8), or IgG3 (n = 23). 
One S fragment was a result of sequential switching to IgG2 
through Sα1.
Figure 1.  Amplifi  cation of S𝗍-S𝗂 breakpoints. A typical run for 
control and ATRD patient. The numbers of μ-α switch fragments were 
determined from 10 PCR reactions run in parallel (lanes 1–10). 11 frag 
ments can be seen in the control (lane 9 has two distinct bands) and 10 in 
ATRD1 (lane 5 has none and lane 10 has two distinct bands). M, molecular 
weight marker.
  Perfectly matched short homology
  0 bp  1-3 bp  4-6 bp  7-9 bp  ≥10 bp
Mutation at 
S junctions
1-bp insertion at 
S junctions
Total no. of 
S fragments
Sμ-Sα
  Controls 67 (44%) 56 (36%) 15 (10%) 11 (7%) 5 (3%) 60 (39%) 39 (25%) 154
  ATRD  16 (41%)  8 (21%)  10 (26%)c 4 (10%)  1 (3%) 7 (18%)d 9 (23%)  39
 A-T  2 (5%)e 15 (34%)  9 (21%)  5 (11%)  13 (30%)e 5 (11%)e 1 (2%)e 44
Sμ-Sγ
  Controls  19 (32%)  37 (63%)  3 (5%)  0 (0%) 0 (0%) 24 (41%) 6 (10%)  59
  ATRD  15 (32%)  25 (53%)  5 (11%)  2 (4%)  0 (0%) 13 (28%) 6 (13%)  47
  A-T  6 (16%) 23 (61%)  7 (18%)d 2 (5%)  0 (0%) 7 (18%)d 3 (8%)  38
aStatistical analysis was performed using χ2 test. Statistically signifi  cant differences are bold.
bParts of the data from A-T patients and controls have been described previously (references 9, 13, 45).
cP < 0.01.
dP < 0.05.
eP < 0.001.
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As in the Sμ-Sα junctions, there was a signifi  cant increase 
in donor–acceptor homology at the Sμ-Sγ junctions from 
ATRD patients (the average length of overlap being 1.8 ± 
2.0 bp vs. 1.2 ± 1.2 bp in controls; P < 0.05, Student’s t 
test). There was a trend toward an increased usage of micro-
homologies (≥4 bp) in the ATRD patients, but not to a sta-
tistically signifi  cant degree (Fig. 2 A and Table I, 11 + 4 + 0 = 
15 vs. 5% in controls). Furthermore, the number of Sμ-Sγ 
junctions that showed mutations (±15 bp) was lower as com-
pared with in controls (28 vs. 41%), whereas insertions were 
observed at a similar rate (13 vs. 12%).
Analysis of mutations in VH-C𝗄 transcripts in ATRD patients
RNA was prepared from PBLs of all three patients. In the 
fi  rst set of experiments, a previously described PCR strategy 
(24) was used to amplify the VH3-Cγ transcripts from 
ATRD3. In total, 14 distinct VH-Cγ clones were generated 
and the majority of these clones carried at least 10 mutations. 
The average frequency of mutations in the VH genes derived 
from this patient was 9.2%, which is higher than that found 
previously in normal controls (n = 7, 1.5–6.6%, average 
4.2%) (24). One notable fi  nding was that the A and T resi-
dues on the coding strand were targeted at a similar frequency 
in the patient (21.9 and 20.8%, respectively; 365 mutations) 
and thus did not display the DNA strand polarity observed in 
controls (29.6 and 13.6%, respectively; 619 mutations).
To verify these fi  ndings, we performed a second set of 
experiments, where all three patients were included. VH3-
23-Cγ transcripts were selectively amplifi  ed to exclude the 
possibility that the diff  erence in A/T base targeting observed 
were because of a diff  erential usage of VH3 genes between 
patients and controls. In total, 33 and 40 distinct VH3-23-Cγ 
clones were generated from B cells of ATRD patients and 
controls, respectively (Table II). Most of the VH3-23 clones 
from the patients were mutated (2–49 bp substitutions/clone) 
and only 6% of the VH3-23 genes exhibited unmutated se-
quences (0–1 bp substitutions/clone) (Fig. 3 A). The frequency 
of mutations in the VH3-23 genes derived from ATRD pa-
tients varied from 6.8 to 11.9%, which is similar to, or slightly 
higher than, the age-matched control donors (Table II). The 
ratio of replacement vs. silent mutations (R/S) in CDRs and 
framework regions was similar in the patient and control 
groups, arguing against any major abnormalities in the anti-
body selection process in ATRD patients.
The distribution of mutations observed in ATRD pa-
tients (754 mutations in total, 22.8/VH) was largely similar to 
that found in normal controls (749 mutations in total, 18.7/
VH), with major hotspots of mutation (AGC and GCT 
at codons Ser32, Ala55, and Ser62), conforming to the previ-
ously described hotspot consensus RGYW/WRYC motif 
(31) (Fig. 3 B). The mutations showed a preference for tran-
sitions in both patients and controls (53 and 56%,  respectively). 
Figure 2.  Microhomology usage at S𝗍-S𝗂 and S𝗍-S𝗄 junctions. 
(A) Pie charts demonstrate the perfectly matched short homology usage 
at Sμ-Sα and Sμ-Sγ junctions in controls, ATRD, and A-T patients. The 
proportion of switch junctions with a given size of perfectly matched 
short homology is indicated by the size of the slices. For clarity, the 4–6 
bp homology portion, which signifi  cantly differs between ATRD and 
controls, is separated from the pie. (B) Accumulative curves indicate the 
microhomology usage at Sμ-Sα junctions in controls, ATRD and A-T 
patients. The percentage of all switch junctions with a given size, using 
perfectly matched short homology, is plotted.JEM VOL. 203, January 23, 2006  103
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However, there were signifi  cantly more transitions occurring 
at T residues in ATRD patients as compared with those in 
controls (11.1 vs. 7.7%, χ2 test, P < 0.05). Furthermore, as 
observed in the VH3 sequences from the fi   rst set of ex-
periments, the A and T residues on the coding strand were 
targeted at a similar frequency (after correcting for base 
com      position, 25.6 and 23.0%, respectively) and thus, the DNA 
strand polarity observed in controls was lost (29.9 and 16.8%, 
respectively) (Fig. 3 C).
To search for a potential diff  erence in the targeting of 
specifi  c sequences between the patients and controls, we fi  rst 
analyzed the frequency of mutations in the RGYW/WRYC 
motifs. A signifi  cantly higher than expected number of muta-
tions (18%) was observed within these motifs, both in pa-
tients and controls (36 and 38%, respectively, χ2 test, P < 
0.0001). However, there seems to be no major diff  erence in 
targeting of the individual bases in these motifs between the 
patients and controls. We subsequently analyzed the targeting 
of the WA/TW motifs and the frequency of mutations within 
these motifs was almost identical between patients and con-
trols (262/754 vs. 261/749, 34%). TA was the most targeted 
motif in both patients and controls. However, there was a 
signifi  cant diff  erence in the targeting of the A or T nucleo-
tide in this motif. In patients, the T and A are equally targeted 
(70 vs. 69 mutations, respectively) whereas in controls, A is 
clearly more targeted (51 T vs. 99 A mutations) (χ2 test, P < 
0.01, Table III). This diff  erence was not observed in the re-
verse complementary motif, AT, nor the other two WA/
TW motifs, AA and TT (unpublished data). When the fl  ank-
ing sequences of each TA motif are taken into account, the 
diff  erence in targeting of the A/T nucleotides within the 
motif was most striking in four short DNA sequences (Table 
III, footnote a). In patients, the T is more targeted than A (34 
vs. 18, respectively) whereas in controls, A is the preferred 
target (19 T vs. 38 A, Table III). Interestingly, the common 
feature of these four sequences is that the TA motif (bold) 
partially overlaps with the RGYW motif (underlined) (i.e., 
two are TAGCA and the remaining two are AGCTAT). 
This suggests that the loss of the A preference on the cod-
ing strand in ATRD patients might be a result of diff  er-
ences in the mechanism generating A/T mutation within 
these sequences.
We subsequently analyzed the frequency of mutations in 
each of the 64 possible trinucleotide combinations (Table S1, 
available at http://www.jem.org/cgi/content/full/jem.
20050595/DC1). The most targeted trinucleotides, in both 
controls and patients, were AGC, GTA, GCT, TAG, and 
GGT. These are all related to the known SHM hotspot mo-
tifs (RGYW/WRYC and WA/TW) (32, 33). Signifi  cant 
diff  erences were observed between the patients and controls 
in targeting the A nucleotides in CTA (↓ in ATRD) and 
TAG (↓ in ATRD) (Table S1), two trinucleotides that are 
included within the TAGCA and AGCTAT sequences, sup-
porting the aforementioned observations on TA motif target-
ing. In addition, signifi  cant diff  erences were found in targeting 
of the trinucleotide TTT ( in ATRD) and the T bases in two 
additional trinucleotides, ATC ( in ATRD) and CTC ( in 
ATRD) (χ2 test, P < 0.05 in all cases). These increases in mu-
tations of T nucleotides may also contribute to the observed 
reduction of the A/T strand bias, although in this instance the 
triplet sequences are not associated with the previously recog-
nized SHM hotspots.
Characteristics of the CDR3 in B cells from ATRD patients
Diversity in the CDR3 region in clones derived from the 
ATRD patients was also analyzed. The CDR3 contains 
contributions from the VH, D, and JH gene segments and 
nucleotides added by TDT. All clones were in-frame rear-
rangements. The average length of the CDR3 was 15.7 ± 
2.9 aa in the ATRD clones, which is similar to those from 
Table II.  Mutations in VH3-23-Cγ transcripts from PBL from ATRD patients and controlsa
Clones Mutations in V region Clustering ratio R/S
Age (yr) All Distinct Unmutated Total % bp CDR/FRb CDRs FRs
ATRD patients
 ATRD1 25 15 13 0 302 8.6 0.73 3.4 1.8
 ATRD2 13 15 14 2 258 6.8 0.73 3.7 1.7
 ATRD3 15 6 6 0 194 11.9 0.62 3.9 2.0
 Total 36 33 2 754 8.4 0.70 3.6 1.8
Controls
 C1 14 12 11 1 100 3.4 1.22 5.9 1.5
 C2 adult 11 11 0 275 9.3 0.73 4.5 1.7
 C3 28 6 6 0 147 9.0 0.69 5.7 2.0
 C4 24 8 8 0 178 8.2 0.51 14.0 2.2
 C5 30 4 4 0 49 4.5 0.53 c 1.1
 Total 41 40 1 749 6.9 0.70 6.2 1.8
aTotal RNA was prepared from PBL from all the patients and controls, except for donor C2; buffycoat was obtained and CD27 positive B cells were used.
bFR, framework region.
cToo few mutations to give a reliable ratio.104  ATR IN CLASS SWITCH RECOMBINATION AND SOMATIC HYPERMUTATION | Pan-Hammarström et al.
controls (14.9 ± 4.2 aa). The average length of the N1 re-
gions (VH-D junctions) was signifi  cantly longer in ATRD 
patients as compared with controls (Student’s t test, P < 0.05; 
Table S2, available at http://www.jem.org/cgi/content/full/
jem.20050595/DC1). There was however no signifi  cant dif-
ference in the length of the N2 regions (D-JH junctions) and 
the frequency of P nucleotides observed between patients 
and controls (Table S2). Thus, the V(D)J coding joints seem 
to be largely normal in ATRD patients.
Functional comparison of ATR and ATM in CSR and SHM
We have previously analyzed the in vivo patterns of CSR 
junctions and mutations in the VH regions in A-T patients 
(ATM defective) using a similar experimental design, (9, 24) 
and these results were compared with those derived from the 
ATRD patients (Table IV).
The number of Sμ-Sα fragments and serum levels of 
immunoglobulins are highly variable in A-T patients (9). 
About half of the patients have no detectable serum IgA, 
Figure 3.  Pattern of mutations introduced in the VH3-23-C𝗄 
transcripts. (A) Pie charts demonstrate the proportion of clones 
  carrying the indicated number of mutations. (B) Distribution of muta-
tions in VH3-23-Cγ transcripts in controls (above the zero line) and 
ATRD patients (below the zero line). Nucleotides are numbered from the 
third base of codon 10 of the VH3-23 coding region. The number of 
mutations at each position is plotted and the major hot spots are 
  highlighed. (C) Nature of base substitutions in the VH3-23 genes. 
The germline sequence used for comparison contains 21.4% A, 31.7% G, 
21.4% T, and 25.5% C. Correction: values presented in the column 
were corrected to represent a sequence with equal amounts of the 
four nucleotides. Statistical analysis was performed using χ2 test. 
Numbers that are signifi  cantly different from controls are bold. 
*P < 0.05, **P < 0.01.JEM VOL. 203, January 23, 2006  105
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whereas the remainder of patients show subnormal to nor-
mal levels of IgA. However, they all show aberrant S junc-
tions, with increased usage of microhomology and reduced 
number of mutations/insertions at the Sμ-Sα junctions (9). 
Thus, the defect in CSR in A-T patients is probably not 
only quantitative, but also qualitative. In ATRD patients, 
the number of Sμ-Sα fragments and serum levels of im-
munoglobulins are normal. However, ATRD2 showed 
low levels of antipneumococcal antibodies after immuni-
zation, which might be due to a less effi   cient switching to 
IgG2 (unpublished data). Furthermore, the Sμ-Sα junc-
tions showed a similar trend in microhomology usage to 
those from A-T patients, although not as dramatic (Fig. 2 
and Tables I and IV). However, the almost complete ab-
sence of 0 bp homologies (4.5% in A-T vs. 41.0% in ATRD, 
χ2 test, P < 0.001) and the large proportion of Sμ-Sα frag-
ments exhibiting ≥10 bp homology (30% in A-T vs. 3% in 
ATRD, χ2 test, P < 0.01) were not found in ATRD pa-
tients. Another notable diff  erence is that although the fre-
quency of junctional mutations (±15 bp) was reduced in 
both patient groups, the proportion of junctions with inser-
tions was reduced in patients with A-T (2 vs. 25% in con-
trols, χ2 test, P < 0.01), but not in those with ATRD (23%). 
Mutations close to the S junctions and 1–3 bp insertions 
thus seem to represent features of diff  erent repair mecha-
nisms. These data indicate that both ATM and ATR are in-
volved in end joining during CSR, but appear to play both 
similar and disparate roles in the process.
The SHM-like mutations in the Sμ regions are signifi  -
cantly reduced in both patient groups. The general pattern 
of base substitutions is altered in A-T patients, with more 
mutations occurring at A/T sites (56 vs. 37% in controls) 
and shows a strong preference for transitions (86 vs. 59%) 
(24). In ATRD patients, there are more mutations occurring 
at G/C (72%) sites, although the rate of transitions is still 
normal (64%). It is also worth noting that the preferred tar-
gets for SHM-like mutations within RGYW/WRCY mo-
tifs (commonly AGCT motifs in these data) are also diff  erent 
between the two patient groups. Almost all the mutations 
in ATRD patients target the second and third nucleotides 
(93%), whereas close to half of the mutations from A-T pa-
tients target the last T in these motifs (42%). In controls, 
83% of the mutations occur at the second and third nucleo-
tides and 5% at the last T in the RGYW/WRCY motifs. 
Therefore, ATR, like ATM, seems to be involved in the 
generation of mutations in the Sμ region, although probably 
via a diff  erent mechanism.
A-T patients show a normal frequency and a largely nor-
mal pattern of SHM in the VH regions (24), whereas in ATRD 
patients, the mutation pattern was clearly altered. As for the 
targeting of individual trinucleotides, A-T patients showed a 
similar pattern as controls (unpublished data), whereas in 
Table III.  Number of mutations at each base of the TA motifs
Controls ATRD
Number of mutations occurring at Number of mutations occurring at
TA motif T A Total T/A T A Total T/A
TA-15 3 7 10 0.4 2 9 11 0.2
TA-133 7 5 12 1.4 7 1 8 7.0
TA-139 10 12 22 0.8 10 8 18 1.3
TACT-154 6 8 14 0.8 5 6 11 0.8
TACTA-158 2 3 5 0.7 3 1 4 3.0
TA-218 2 9 11 0.2 5 6 11 0.8
TA-258 2 12 14 0.2 4 14 18 0.3
TA-260 0 2 2 0 0 2 2 0
TA-263 0 3 3 0 0 4 4 0
Total 32 61 93 0.5 36 51 86 0.7
TAGCA-67a 2 4 6 0.5 8 5 13 1.6
AGCTAT-74a 3 10 13 0.3 3 5 8 0.6
AGCTAT-130a 51 01 50 . 51 1 31 43.7b
TAGCA-148a 9 14 23 0.6 12 5 17 2.4b
Total 19 38 57 0.5 34 18 52 1.9c
TA-Total 51 99 150 0.5 70 69 139 1.0d
Statistical analysis was performed using χ2 test. T/A ratios that are signifi  cantly different from controls are bold. TA motifs analyzed are bold and the RGYW/WRCY motifs 
are underlined.
aTA motif that is partially overlaps with a RGYW motif.
bP < 0.05.
cP < 0.001.
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ATRD patients the targeting of A or T bases in certain trinu-
cleotides was signifi  cantly altered.
DISCUSSION
In this study, we have, for the fi  rst time, shown a role for 
ATR in CSR and SHM. The study also revealed interesting 
functional diff   erences between ATM and ATR-mediated 
signaling; the ATM-dependent pathway is mainly used in the 
end joining process in CSR, whereas the ATR-dependent 
pathway appears to be involved in both CSR and SHM.
The functional roles of ATM and ATR have been exten-
sively studied in the general DNA damage response. Both are 
structurally and functionally related with overlapping sub-
strates and have therefore been suggested to operate within 
the same pathway (21, 34, 35). However, while ATM exclu-
sively responds to DSBs induced by ionizing radiation and 
some radiomimetic agents, ATR is also activated by single-
stranded DNA (ssDNA) generated during DNA replication 
or by agents such as UV irradiation that produce bulky le-
sions (35, 36). There also seem to be kinetic diff  erences be-
tween the two kinases when responding to diff  erent forms of 
DNA damage. Both ATM and ATR phosphorylate p53 on 
serine-15 in response to ionizing radiation, but ATM initiates 
the process whereas ATR dominates the phosphorylation 
process at later stages (36). However, in response to a meth-
ylating agent, temozolomide, ATM is activated later than 
ATR (37). Furthermore, the function of ATR is dependent 
on an accessory protein, ATRIP (ATR-interacting protein), 
which is phosphorylated by ATR (38).
The diff  erent pattern of CSR junctions and SHM in the 
VH regions, when ATM or ATR is defective, could poten-
tially be explained by the known diff  erences between the two 
kinases. In CSR, a DSB intermediate appears to be part of the 
reaction (39), and ATM may thus play a major role in the 
initial stage of the repair process. However, by responding to 
the ssDNA resulting from processed DSBs, ATR will rein-
force the ATM response, resulting in a potentiation of the re-
action. In SHM, DSBs seem not to be prominent intermediates, 
instead, SSBs or single strand nicks appear to be essential (40–
42). ATM, which only responds to DSBs, is thus dispensable 
for the SHM process. Alternately, ATR, when complexed 
with ATRIP, is recruited to ssDNA by RPA (43), a factor 
that targets AID to SHM motifs (44). When ATR activity 
is absent, or impaired (as in our patients, who carry hypo-
morphic mutations), the SHM pattern is perturbed.
The diff  erent patterns of Sμ-Sα junctions in A-T and 
ATRD patients may help to further dissect the four end join-
ing pathways we have previously proposed (9, 45). The fi  rst 
pathway entails a “blunt end” direct joining mechanism, 
where no sequence homology is needed and the two DNA 
ends are either joined precisely or where 1–3 bp (mostly 1 
bp) insertions are introduced. The second pathway in-
volves joining of partially complementary “staggered” DNA 
ends by a mechanism involving alignment of residual com-
plementarities (1–3 bp) in 3′ or 5′ overhangs, fi  lling in of any 
remaining gaps and ligation. This process is imprecise, and 
mutations are frequently introduced at, or close to, the switch 
junctions. The third pathway has precise joining of comple-
mentary DNA ends with a short sequence homology (1–3 
bp), probably through simple religation, with no mutations 
or insertions being introduced at, or close to, the junctions. 
The fourth pathway is an alternative joining of noncomple-
mentary ends, by resecting the DNA ends until homology 
suitable for end joining is revealed where at least 4 bp of mi-
crohomology is observed at the S junction. In B cells from 
healthy individuals, the fi  rst pathway is dominant (44% of 
Sμ-Sα events) and the other three are used with similar fre-
quencies ( 20%). The fi  rst pathway, “blunt end” direct join-
ing is markedly impaired in A-T patients, but normal in 
ATRD patients, suggesting that this process is strictly depen-
dent on a rapid, effi     cient response by ATM. The second 
Table IV.  Roles of ATM and ATR in CSR, SHM, and 
V(D)J recombination
A-T patients ATRD patients
CSR
  Serum IgA and IgG level Not detectable to 
 normal
Normal
  No. of clones switched 
  to  IgA
↓a to Normal Normal
 S μ-Sα junctions
  Average  microhomology ↑b 7.2 ± 6.0 bp ↑a 3.0 ± 3.8 bp
  Shift  of  Sμ breakpoints Yesb Yesc
  Junctional  mutations ↓c ↓a
  Junctional  insertions ↓c Normal
 S μ-Sγ junctions
  Average  microhomology ↑b 2.5 ± 1.7 bp ↑a 1.8 ± 2.0 bp
  Junctional  mutations ↓a (↓)
  Junctional  insertions (↓) Normal
  SHM-like mutation in 
  S μ region
  Frequency ↓b ↓b
  Pattern Altered,  A/T  biased, 
 transition  biased
G/C biased 
 ( ↓) A mutations
SHM
 Frequency Normal (↑)
  Pattern Largely normal Altered, lost A/T 
 strand  bias
V(D)J recombination
  Coding joints Normal Largely normal, 
  ↑a length of N1 
 region
Statistical analysis was performed using χ2 test or Student’s t test (for average 
length of microhomology). The numbers that are signifi  cantly different from 
controls are marked by or ↓. (↑) or (↓), increased or decreased as compared to the 
controls, but not to a statistically signifi  cant degree.
aP < 0.05.
bP < 0.001.
cP < 0.01.JEM VOL. 203, January 23, 2006  107
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(“staggered end” joining involving misalignment and fi  lling 
in) pathway is less often used in both A-T and ATRD pa-
tients (9 and 3%, respectively, as compared with 16% in con-
trols), suggesting that both ATM and ATR are required for 
processing of partially complementary ends. The third path-
way, involving simple religation, is not aff  ected. However, 
usage of the fourth pathway, involving ≥4 bp microhomol-
ogy, is increased in both patient groups (61 and 38%, respec-
tively, as compared with 20% in controls). Interestingly, in 
contrast with A-T patients, the CSR junctions from ATRD 
patients only show an increased usage of microhomology up 
to 9 bp, suggesting that there may be yet another pathway 
or subpathway, requiring longer microhomologies (≥10 bp), 
that may be dependent on ATR.
Although the aforementioned end joining pathways in 
CSR are still speculative, it could provide a platform when 
comparing data from patients with genetic defects that aff  ect 
specifi  c DNA damage response pathways. In patients lacking 
DNA ligase IV, a critical component of the NHEJ machin-
ery, the pattern of Sμ-Sα junctions is similar to that of A-T 
patients (45). The fi  rst and second pathways are almost not 
used at all, the third pathway is not aff  ected (20%), and the 
fourth pathway is dominant (73%), suggesting that the “blunt 
end” and “staggered end” joining with short, noncomple-
mentary ends are strictly dependent on the classical NHEJ 
machinery. The third pathway, which is not aff  ected  by 
ATM, ATR, or DNA ligase IV, is impaired in NBS (Nbs1 
defective, 4%) and, to a lesser degree, in ATLD patients 
(Mre11 defective, 11%) (13), suggesting that simple religation 
involving short homologous ends in CSR is probably, as de-
scribed in the yeast system (46), dependent on the Mre11–
Rad50–Nbs1 complex.
However, the balance between these putative diff  erent 
pathways is dependent not only on the factors available but 
also on the degree of homology between the S regions. The 
microhomology based end joining is much more prominent 
at Sμ-Sα as compared with Sμ-Sγ junctions in all patient 
groups, probably because of the higher degree of homology 
between Sμ and Sα as compared with Sμ and Sγ regions 
(45). The likelihood of obtaining a 7-, 10-, or 15-bp 
microhomology between the Sμ-Sα regions is 8, 270, and 
>1,000-fold higher than in the Sμ-Sγ regions. Furthermore, 
the mutation pattern at, or close to, the Sμ-Sγ junctions is 
also diff  erent from the Sμ-Sα junctions in normal controls 
(45, 47). Moreover, in A-T and ATRD patients, the Sμ-Sγ 
junctions tend to use more microhomologies, whereas in 
Lig4D patients, the Sμ-Sγ junctions mainly show an in-
creased frequency of 1-bp insertions (45). Thus, the Sμ-Sα 
and Sμ-Sγ junctions are resolved diff  erently in controls and 
patients with various defects in their DNA repair systems. In 
mice, the Sα regions also show a much higher degree of ho-
mology with Sμ, than does Sγ, and the microhomology-
based pathway would be a more attractive alternative for 
Sμ/Sα recombination when the normal repair pathways is 
impaired. However, in the various mouse knockout models 
described to date, Sμ-Sα junctions have not been analyzed in 
as much as detail as Sμ-Sγ1 and Sμ-Sγ3 junctions (10, 11, 
16–18, 48). An analysis of Sμ-Sα junctions from mouse B 
cells defi  cient for H2AX and 53BP1, where no equivalent 
human disease model is available, would thus facilitate our 
understanding of the regulation of ATM–ATR-dependent 
pathways in CSR.
The loss of strand polarity in targeting A/T pairs in the 
VH regions from ATRD patients is an interesting fi  nding. 
The mechanism underlying the strand polarity at A/T pairs 
(i.e., with mutations at A on the coding strand being nearly 
twice as frequent as mutations at T [32]) is not well under-
stood. One possibility is that the A/T bias is a consequence of 
an initial preferential targeting of dCs by AID in the nontran-
scribed strand (49). Alternatively, it may refl  ect the strand 
preference of transcription-linked repair, where an abasic site 
created by excising a U residue from the transcribed DNA 
strand of U-A pairs is treated diff  erently (repaired or mutated) 
from an abasic site located on the nontranscribed strand (42). 
Because ATR and AID can both associate with RPA, this 
raises several possible explanations; ATR could be acting as 
early as at the initial AID targeting stage by phosphorylating 
RPA (50) or by regulating its intranuclear translocation (51). 
Alternately, RPA recruits ATR–ATRIP complex to sites of 
DNA damage (43) so ATR involvement could be postinitia-
tion. Two other PIKKs kinases, ATM and DNA-PKcs, have 
also been implicated in the DNA damage-induced phosphor-
ylation of RPA (for review see reference 52). However, as 
the SHM patterns are largely normal in cells defi  cient  in 
ATM or DNA-PKcs (24, 25), their kinase activities are prob-
ably not required in this process. An alternative role for ATR 
could be at a later stage, by interacting with or recruiting 
members of the mismatch repair pathway, such as MSH2 (53, 
54) and MSH6 or polymerase (pol) η, all of which have been 
implicated in generating mutations at A/T sites (42, 55–57). 
Pol η in particular is thought to contribute to strand bias of A 
versus T nucleotides by generating more mutations from A 
than T on the nontranscribed strand (58). However, cells de-
fi  cient in various mismatch repair proteins and pol η show 
reduced rates of mutation at both A and T nucleotides (42, 
56), whereas in ATRD cells, the mutation load on A and T 
nucleotides is normal but an increased ratio of T/A targeting 
is observed. Loss of strand bias has also previously been noted 
in a mutating B cell line, Ramos (59). Interestingly, the ATR 
gene is not expressed in this cell line, whereas MSH2, MSH6 
(unpublished data) and pol η (60) transcripts are readily de-
tected. However, the pattern of mutations observed in Ra-
mos cells is strongly biased to G/C (82%), similar to those in 
MSH2, MSH6, or pol η–defi  cient cells, suggesting that in 
addition to ATR, defi  ciency of other DNA repair factors 
may account for the mutation pattern observed in this cells 
line. Together, ATR is unlikely to be an “A/T mutator,” 
but rather, recruits “A/T mutators,” such as pol η, preferen-
tially to the transcribed strand at specifi  c sequences. Because 
ATR may be linked to AID via RPA, it is logical that its 
  eff   ects are more noticeable near the AID target motifs 
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loss of ATR reduces A/T strand bias at the TAGCA or 
AGCTAT sequences.
Another possibility that needs to be excluded is that the 
altered mutation pattern in ATRD cells is the result of a bias 
introduced by studying only the expressed VH genes. To ad-
dress this question, an analysis of the noncoding regions of the 
heavy chain locus such as the JH4 intron sequence (57) was 
attempted. We were able to obtain a small number of purifi  ed 
CD27+ B cells from two patients, ATRD1 and ATRD2, and 
amplifi  ed the JH4 intron sequence downstream of the rear-
ranged VH3-23 gene as described previously (57). In controls 
(n = 5), an average frequency of 16/1,000 bp of mutations 
was observed, which is similar to that published previously 
(57). However, very few mutations were identifi  ed in the pa-
tients even after screening a large number of clones (n = 66), 
precluding the possibility to compare the mutation pattern. 
Nevertheless, although WA motifs are common in the 320 
bp of the JH4 intron sequence, there are only three TA mo-
tifs and none of these is associated with the RGYW motif. 
Thus, one would not expect to reproduce the specifi  c pattern 
observed in the VH regions in ATRD patients.
The Sμ region is another noncoding region that has been 
used to analyze nonselected, SHM-like mutations (56, 57). In 
the limited number of mutations we observed in the Sμ re-
gion, away from the breakpoints, we did observe a reduced 
number of mutations at A nucleotides (T/A ratio 1:1). How-
ever, the SHM-like mutations observed in the Sμ region are 
probably introduced at an early stage during CSR, in a pro-
cess that may share some of the factors with SHM but which 
is still mechanistically diff  erent (24). Thus, an altered muta-
tion pattern in the Sμ region may not necessarily be the result 
of changes in the SHM machinery.
The Seckel syndrome is a clinically and genetically het-
erogeneous disorder where at least four susceptibility loci 
have been suggested (63–66). To date however, mutation in 
ATR is the only genetic defect identifi  ed. Of the 70 patients 
described worldwide, only 5 patients carry mutations in the 
ATR gene. However, a recent study has shown that there are 
remarkably overlapping phenotypes between a panel of 
Seckel syndrome cell lines (with no defect in ATR) and an 
ATRD-Seckel cell line (67), suggesting that the disease is in-
deed caused by defects in the ATR-signaling pathway. It 
would therefore be of considerable interest to study the CSR 
and SHM patterns in additional patients with the Seckel syn-
drome, where the gene mutated may be one of the other fac-
tors involved in the ATR-dependent pathway, including 
ATRIP, RPA, RAD17, chk1, 53BP1, and H2AX.
In conclusion, V(D)J recombination, SHM and CSR 
may share some of the molecular mechanisms involved but 
are diff  erentially regulated. ATR is probably dispensable for 
V(D)J recombination, but may play some role in the end 
joining machinery in CSR and in SHM.
MATERIALS AND METHODS
Patient material. The study included three patients from one family with 
Seckel syndrome with mutations in the ATR gene. The clinical details of the 
patients (ATRD1, ATRD2, and ATRD3 referred to as V3, V6 and V4 in 
reference 66) have been described previously (26, 66). The mutation in the 
ATR gene in these patients is a homozygous replacement within exon 9 
(2101 A>G) that alters ATR splicing, resulting in markedly reduced levels of 
normal transcripts and protein (26). The serum levels of immunoglobulin 
classes are normal in the studied patients (66). Lymphocyte count was avail-
able from one patient, ATRD2, and the number of B cells was slightly above 
the upper normal range, whereas the number of T cells was at the lower nor-
mal range. The genetic characterization and immunoglobulin levels in the 
A-T patients discussed in this study have all been described previously (8, 9). 
The institution review board at the Karolinska Institute approved the study.
Amplifi  cation of S𝗍-S𝗂 and S𝗍-S𝗄 fragments. Genomic DNA was 
purifi  ed from peripheral blood cells from the ATRD patients. The amplifi  -
cation of Sμ-Sα fragments from in vivo switched cells was performed as 
described previously (9, 30). In brief, two pairs of Sμ- and Sα-specifi  c 
primers were used in a nested PCR assay. The number of Sμ-Sα fragments 
was determined from 10 reactions run in parallel using DNA (30 ng per re-
action) from each individual and represents a random amplifi  cation of in 
vivo switched clones. The number of IgA positive cells in 30 ng of genomic 
DNA prepared from normal peripheral blood cells was estimated to be 30–
60 (assuming that 40% peripheral blood cells are lymphocytes, 10–20% of 
the lymphocytes are B cells and 5% of the B cells are IgA+). One or two 
Sμ-Sα fragments were normally amplifi  ed in one lane, when 30 ng of 
DNA was added in one reaction. This sensitivity, 15–30 copies, is in the 
same order of sensitivity as we have previously estimated using a human 
IgA1–producing cell line (30). The same cell line was also used to assess the 
fi  delity of the nested PCR reaction and the PCR error rate was 0.9/1,000 
nucleotides (30).
The Sμ-Sγ fragments were amplifi  ed as described previously (68) with 
addition of Sγ1-specifi  c and Sγ2-specifi  c primers (45).
Analysis of the S𝗍-S𝗂 and S𝗍-S𝗄 junctions. The PCR-amplifi  ed S 
fragments were gel purifi  ed, cloned, and sequenced as described previously 
(9). The breakpoints were determined by aligning the switch fragment se-
quences with the Sμ (X54713)/Sα1 (L19121)/Sα2 (AF030305) or Sμ/Sγ1 
(U39737)/Sγ2 (U39934)/Sγ3 (U39935)/Sγ4 (Y12547-52) sequences. 
Analysis of microhomology usage at the junctions and mutations ±15 bp 
around the junction and upstream Sμ region were performed as described 
previously (9, 24).
RNA isolation and PCR amplifi  cation of VH3-C𝗄 transcripts. Total 
RNA was extracted from PBL using RNeasy RNA purifi  cation kits (QIA-
GEN) and fi  rst-strand cDNA synthesis was performed with a CγA primer (5′-
G  T  C  C  T  T  G  A  C  C  A  G  G  C  A  G  C  C  C  A  G  -3′) using a cDNA synthesis kit (GE 
Healthcare). The primers used for amplifi  cation of VH3-Cγ and VH3-23-Cγ 
transcripts were VH3-consensus (5′-aatctagaG  G  T  G  C  A  G  C  T  G  G  T  G  G  A  G-
T  C  -3′) or VH3-23 (5′-tctagaG  G  C  T  G  A  G  C  T  G  G  C  T  T  T  T  T  C  T  T  G  T  G  G  -3′) 
and CγB (5′-cagtcgacA  A  G  A  C  C  G  A  T  G  G  G  C  C  C  T  T  G  G  T  G  G  -3′). The oli-
gonucleotides contained a restriction site, (underlined, a XbaI site in the VH3-
consensus or VH3-23 primer and a SalI site in the CγB primer) for directional 
cloning of the PCR products. Amplifi  cation was performed in 35 cycles, each 
cycle consisting of 94°C for 50 s, 62°C for 1 min, and 72°C for 1 min. A high 
fi  delity Vent DNA polymerase (New England BioLabs) was used in all PCR 
amplifi  cations of the VH region transcripts.
Analysis of the VH-C𝗄 clones. The PCR products were purifi  ed and 
cloned into the Bluescript II KS (+) vector (Stratagene) and transformed into 
JM 109 competent cells. The resulting clones were screened by PCR ampli-
fi  cation (VH3-consensus/VH3-23 and CγB) and positive clones were se-
quenced by an automated fl  uorescent sequencer in the MWG Co. using a 
Bigdye terminator cycle sequencing kit (Perkin Elmer). Sequence analysis was 
performed using the IMGT/V-QUEST (http://imgt.cines.fr) (69) to align 
the VH-CγB sequences to their closest germline VH, D, and JH segment 
counterparts. The immunoglobulin V(D)J junctional sequences were ana-
lyzed by the IMGT/JunctionAnalysis tool, available at http://imgt.cines.fr.JEM VOL. 203, January 23, 2006  109
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When analyzing the trinucleotides targeting, mutated VH3-23 se-
quences were aligned beneath the germline VH3-23 region gene and a raw 
test fi  le of the alignment created. This fi  le was imported into a Microsoft 
Excel spreadsheet and computations of the number of each type of nucleo-
tide substitution and the composition of the fl   anking sequences around 
these substitutions were performed using macros in Excel (Visual Basic). 
Computations of percentage diff  erences and χ2 analysis were also performed 
using Excel.
Online supplemental material. Table S1 shows the number of mutations 
at each base of all trinucleotides. Table S2 shows the characteristics of the 
CDR3 regions in cells from ATRD patients and controls. Fig. S1 shows the 
sμ-sα junctions from ATRD patients. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20050595/DC1.
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